{"id":6280,"date":"2024-08-06T15:08:00","date_gmt":"2024-08-06T15:08:00","guid":{"rendered":"https:\/\/dailywashingtoninsider.com\/index.php\/2024\/08\/06\/biomarker-technologies-for-cardiovascular-health\/"},"modified":"2024-08-06T15:08:00","modified_gmt":"2024-08-06T15:08:00","slug":"biomarker-technologies-for-cardiovascular-health","status":"publish","type":"post","link":"https:\/\/dailywashingtoninsider.com\/index.php\/2024\/08\/06\/biomarker-technologies-for-cardiovascular-health\/","title":{"rendered":"Biomarker Technologies for Cardiovascular Health"},"content":{"rendered":"<p><strong>Cardiex Limited<\/strong> (ASX:CDX) (the \u201cCompany\u201d) is pleased to present its investor presentation. <\/p>\n<p><strong>June 2024 Quarterly Highlights <\/strong><\/p>\n<p><strong>Record annual company revenues \u2013 $12.4m.<\/strong><\/p>\n<p>Initial Pulse units arrived in USA &amp; Australia.Marketing and demand generation campaigns driving awareness and demand.New partnerships and pilot programs.Initial Pulse production run increased to 8,000 (previously 3,000). Pre-submission phase for OTC FDA-clearance for the Pulse. New patent awarded by USPTO for wearable PPG sensor technology.Nearing completion of our wearable sensor validation study.FDA submission for wearable technology anticipated Q1 25. <\/p>\n<div><\/div>\n<p><strong>Financial Overview (Q4 ending 30 June 2024)<\/strong><\/p>\n<p>Revenue and other income for FY24 of $12.4m (FY23 &#8211; $6.0m)Q4 operating cash outflows of $2.8m, being a significant reduction to the Q3 normalized operating outflows of $3.4m, due to:Higher cash receipts of $0.9m in Q4 vs $0.7m in Q3, andFY23 R&amp;D tax incentive of $0.7m.Cash resources and reserves ~ $6.5m, comprising:$0.5m cash; and$6.0m being funded under the Funding Commitment Agreement with C2 Ventures.Cash resources are believed to be sufficient to fund the Company\u2019s growth initiatives, its operations, and to meet its business objectives. <\/p>\n<\/p>\n<p><strong>Click here for the full ASX Release<\/strong><\/p>\n<\/p>\n<div>This post appeared first on investingnews.com<\/div>\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Cardiex Limited (ASX:CDX) (the \u201cCompany\u201d) is pleased to present its investor presentation. June 2024 Quarterly&hellip;<\/p>\n","protected":false},"author":1,"featured_media":6281,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[25],"tags":[],"class_list":["post-6280","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-investing"],"_links":{"self":[{"href":"https:\/\/dailywashingtoninsider.com\/index.php\/wp-json\/wp\/v2\/posts\/6280","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dailywashingtoninsider.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dailywashingtoninsider.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dailywashingtoninsider.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dailywashingtoninsider.com\/index.php\/wp-json\/wp\/v2\/comments?post=6280"}],"version-history":[{"count":0,"href":"https:\/\/dailywashingtoninsider.com\/index.php\/wp-json\/wp\/v2\/posts\/6280\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dailywashingtoninsider.com\/index.php\/wp-json\/wp\/v2\/media\/6281"}],"wp:attachment":[{"href":"https:\/\/dailywashingtoninsider.com\/index.php\/wp-json\/wp\/v2\/media?parent=6280"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dailywashingtoninsider.com\/index.php\/wp-json\/wp\/v2\/categories?post=6280"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dailywashingtoninsider.com\/index.php\/wp-json\/wp\/v2\/tags?post=6280"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}